2023
Biological treatment for bullous pemphigoid
Oren-Shabtai M, Mimouni D, Nosrati A, Atzmony L, Kaplan B, Barzilai A, Baum S. Biological treatment for bullous pemphigoid. Frontiers In Immunology 2023, 14: 1157250. PMID: 37180101, PMCID: PMC10172582, DOI: 10.3389/fimmu.2023.1157250.Peer-Reviewed Original ResearchConceptsBullous pemphigoidImmunosuppressive therapyPatients treated with rituximabLong-term corticosteroid useAdjuvant immunosuppressive therapyConventional immunosuppressive therapySteroid-sparing agentsAutoimmune subepidermal bullous diseaseFirst-line treatmentPrevious treatment failuresSeries of patientsFollow-up periodFollow-up visitSignificant side effectsNo adverse eventsSubepidermal bullous diseasesBP durationRecalcitrant BPRituximab coursesSystemic corticosteroidsClinical responseTreatment failureCorticosteroid useImmunobiological therapyBiologic therapy
2017
Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature
Snast I, Atzmony L, Braun M, Hodak E, Pavlovsky L. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature. Journal Of The American Academy Of Dermatology 2017, 77: 88-97.e5. PMID: 28495497, DOI: 10.1016/j.jaad.2017.01.037.Peer-Reviewed Original ResearchConceptsChronic HBV infectionBiologic therapyHBV infectionViral reactivationAntiviral prophylaxisCore antibodyHCV infectionHepatitis BSafety of biologic therapiesHistory of viral hepatitisSystematic reviewIsolated core antibodyHBV core antibodyLow-risk patientsRetrospective cohort study designRetrospective cohort studyReactivated HBV infectionCohort study designPsoriasis patientsViral hepatitisEvaluate safetyFollow-upCohort studyPrimary outcomeTreatment duration